Literature DB >> 21886505

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.

Mary Beth Beasley1, Daniel T Milton.   

Abstract

ASCO has recently provided guidance on emerging data on EGFR testing for the purpose of selecting first-line therapy for persons with advanced NSCLC through its Provisional Clinical Opinion.

Entities:  

Year:  2011        PMID： 21886505      PMCID： PMC3092665          DOI： 10.1200/JOP.2010.000166

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  20 in total

1.  Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

Authors:  Miguel Taron; Yukito Ichinose; Rafael Rosell; Tony Mok; Bartomeu Massuti; Lurdes Zamora; Jose Luis Mate; Christian Manegold; Mayumi Ono; Cristina Queralt; Thierry Jahan; Jose Javier Sanchez; Maria Sanchez-Ronco; Victor Hsue; David Jablons; Jose Miguel Sanchez; Teresa Moran
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.

Authors:  Takashi Sone; Kazuo Kasahara; Hideharu Kimura; Kazuto Nishio; Masayuki Mizuguchi; Yasuto Nakatsumi; Kazuhiko Shibata; Yuko Waseda; Masaki Fujimura; Shinji Nakao
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

3.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

4.  Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Takahiro Nakajima; Kazuhiro Yasufuku; Makoto Suzuki; Kenzo Hiroshima; Rieko Kubo; Sherif Mohammed; Yohei Miyagi; Shoichi Matsukuma; Yasuo Sekine; Takehiko Fujisawa
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

5.  Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

Authors:  Vincent A Miller; Gregory J Riely; Maureen F Zakowski; Allan R Li; Jyoti D Patel; Robert T Heelan; Mark G Kris; Alan B Sandler; David P Carbone; Anne Tsao; Roy S Herbst; Glenn Heller; Marc Ladanyi; William Pao; David H Johnson
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

Review 6.  EGFR assays in lung cancer.

Authors:  Sanja Dacic
Journal:  Adv Anat Pathol       Date:  2008-07       Impact factor: 3.875

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.

Authors:  Laura Boldrini; Silvia Gisfredi; Silvia Ursino; Tiziano Camacci; Editta Baldini; Franca Melfi; Gabriella Fontanini
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

9.  Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule.

Authors:  Hirofumi Nakano; Hiroshi Soda; Mineyo Takasu; Nanae Tomonaga; Hiroyuki Yamaguchi; Katsumi Nakatomi; Satoru Fujino; Tomayoshi Hayashi; Yoichi Nakamura; Kazuhiro Tsukamoto; Shigeru Kohno
Journal:  Lung Cancer       Date:  2007-09-24       Impact factor: 5.705

10.  EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer.

Authors:  Jason H Smouse; Edmund S Cibas; Pasi A Jänne; Victoria A Joshi; Kelly H Zou; Neal I Lindeman
Journal:  Cancer       Date:  2009-02-25       Impact factor: 6.860
View more
  9 in total

1.  Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).

Authors:  Guoming Wu; Caicun Zhou; Chunxue Bai; Guisheng Qian
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  How and when to use genetic markers for nonsmall cell lung cancer.

Authors:  Donald R Lazarus; David E Ost
Journal:  Curr Opin Pulm Med       Date:  2013-07       Impact factor: 3.155

3.  Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.

Authors:  Julian C Schink; Julia R Trosman; Christine B Weldon; Kalliopi P Siziopikou; Gregory J Tsongalis; Alfred W Rademaker; Jyoti D Patel; Al B Benson; Edith A Perez; William J Gradishar
Journal:  J Natl Cancer Inst       Date:  2014-09-12       Impact factor: 13.506

4.  Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer.

Authors:  Shih-Hsin Hsiao; Sey-En Lin; Yu-Ting Chou; Jinn-Li Wang; Chi-Li Chung; Ming-Chih Yu; Chia-Lang Fang; Hsin-Lun Lee; Ling-Ling Chiang; H Eugene Liu; Cheng-Wen Wu
Journal:  Mol Clin Oncol       Date:  2013-12-23

Review 5.  Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine.

Authors:  Donna M Graham; Natasha B Leighl
Journal:  Front Oncol       Date:  2014-09-22       Impact factor: 6.244

6.  Effects of a Multidisciplinary Approach to Improve Volume of Diagnostic Material in CT-Guided Lung Biopsies.

Authors:  Philip E Ferguson; Catherine M Sales; Dalton C Hodges; Elizabeth W Sales
Journal:  PLoS One       Date:  2015-10-19       Impact factor: 3.240

7.  Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate.

Authors:  Maria E Arcila; Soo-Ryum Yang; Amir Momeni; Douglas A Mata; Paulo Salazar; Roger Chan; Daniela Elezovic; Ryma Benayed; Ahmet Zehir; Darren J Buonocore; Natasha Rekhtman; Oscar Lin; Marc Ladanyi; Khedoudja Nafa
Journal:  JTO Clin Res Rep       Date:  2020-07-18

Review 8.  [Research progress of the relationship between tumor suppressor gene 
 PTEN and non-small cell lung cancer].

Authors:  Yanan Li; Hongwu Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-03

9.  EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.

Authors:  Kara L Larson; Bin Huang; Quan Chen; Thomas Tucker; Marissa Schuh; Susanne M Arnold; Jill M Kolesar
Journal:  PLoS One       Date:  2020-08-18       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.